Navigation Links
InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights
Date:1/5/2012

Austria.  The net ex-factory price of Esbriet in Denmark is more than 35,000 euro, or just over $47,000 per patient, per year.  

InterMune currently is expanding its commercial infrastructure to support launches in the mid-sized EU countries.  The company currently expects to have a total headcount in the range of approximately 160 to 190 in its EU infrastructure by the end of the third quarter of 2012, assuming that country launches occur as planned.


New Efficacy Data of Esbriet in IPF: RECAP

RECAP is an ongoing open-label extension study, looking at the long-term administration of Esbriet in patients who completed the Phase 3 CAPACITY program.

Long-term safety results from RECAP were presented at the Annual Congress of the European Respiratory Society (ERS) in September 2011.  These results demonstrated that long-term treatment with Esbriet was safe and generally well-tolerated, with a long-term safety profile similar to that observed in CAPACITY.

New analyses of change in FVC and Survival in patients who received placebo in CAPACITY and were newly treated with Esbriet in RECAP have now been conducted.  These new efficacy analyses show that the patients with mild-to-moderate IPF newly treated with Esbriet in RECAP for 60 weeks, have similar FVC and survival outcomes when compared to those treated with Esbriet in CAPACITY for the same duration.

The analyses specifically examined the proportion of patients at Week 60 who experienced an FVC decline of 10% or greater, an outcome that is highly clinically relevant and predictive of mortality.  Patients treated with Esbriet in RECAP had outcomes that were similar to those treated with Esbriet in CAPACITY, and the proportion of patients experiencing FVC decrements of 10% or greater was approximately 40% lower than in the CAPACITY placebo group.  Overall survival of patients treated with Esbriet in RECAP was similar to that in
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. InterMune Appoints Angus C. Russell to Board of Directors
2. InterMune to Release Third Quarter Financial Results on November 3
3. InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
4. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
5. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
6. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
7. InterMune to Present at J.P. Morgan Healthcare Conference
8. InterMune Reports Third Quarter 2010 Financial Results
9. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
10. InterMune to Release Second Quarter Financial Results on July 27
11. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... BURLINGTON, Mass., Dec. 12, 2011 /PRNewswire-iReach/ -- ... Financial. Tom joined Ametros as executive vice president in ... in the workers, compensation managed care industry. He served ... Medical, vice president of national occupational health for Kaiser ...
... Ontario, Dec. 12, 2011  Valeant Pharmaceuticals International, Inc. ... at a special meeting of shareholders of Afexa ... today in Calgary, Alberta, the shareholders of Afexa ... subsidiary, 1625907 Alberta Ltd. (the " Offeror ") ...
Cached Medicine Technology:Ametros Financial Names Thomas Ash as CEO 2Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc. 2Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc. 3
(Date:4/18/2014)... have been awarded two-year grants for their work on ... Of the 110 initial submissions to the new Novo ... four projects were funded, three of which are led ... Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, M.D., ... will use his $500,000 proof of principle grant to ...
(Date:4/18/2014)... available in French . ... practice and regenerative medicine. A team led by Ludwik ... Paris Tech) and Didier Letourneur from the Laboratoire Recherche ... just demonstrated that the principle of adhesion by aqueous ... repair soft-tissue organs and tissues. This easy-to-use gluing method ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... 2014) Doctors who treat patients with a ... can face an agonizing treatment decision. , The ... and help relieve shortness of breath. But some ... can cause potentially fatal complications following transplantation. , ... Dilling, medical director of Loyola University Medical Center,s ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... the arm by way of a novel research conducted by ... endowed with the potential to inhibit the growth of blood ... may throw open a plethora of options to fight cancer ... University, previous research has indicated the benefits of aspirin in ...
... down for decades, ever since studies showed a strong link ... experts have suggested that some people should aim even lower, ... called low-density lipoprotein for some high-risk people — even if ... there. ,Not so fast, says a team of researchers ...
... Among patients with schizophrenia whose medication is changed ... antipsychotic drugs do not appear to offer significant ... a report in the October issue of Archives ... ,The findings run contrary to the ...
... less than 2,000 grams (about 4.5 pounds) at birth ... the average teenager to have physical and mental difficulties, ... Archives of Pediatrics & Adolescent Medicine, one of the ... increase the risk for major disabilities such as cerebral ...
... unexplored regions of the human genome are thousands of ... growth of breast cancer is driven by estrogen, new ... ,In the October issue of Nature Genetics, the investigators ... panels" -- stretches of DNA that turn genes on ...
... has apologized to a woman who had a miscarriage in ... to go through the process.// ,On Tuesday Health region ... are sorry that this situation occurred and we empathize with ... the circumstances of this case, as we do with all ...
Cached Medicine News:Health News:No Clear Evidence for Ultra-Low Cholesterol Targets? 2Health News:No Clear Evidence for Ultra-Low Cholesterol Targets? 3Health News:No Clear Evidence for Ultra-Low Cholesterol Targets? 4Health News:New Antipsychotic Medications have Little Advantage Over Older Drugs 2Health News:New Antipsychotic Medications have Little Advantage Over Older Drugs 3Health News:Low Birth Weight Babies May Have Mental & Physical Problems 2Health News:New Tool for Understanding Estrogen-Fueled Breast Cancer 2Health News:New Tool for Understanding Estrogen-Fueled Breast Cancer 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: